-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026

Benzinga·07/29/2025 11:41:24
Listen to the news

Financial update

The following is a summary of the Appendix 4C Cash Flow Report:

  • The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.
  • Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and Staff Costs comprised over 90% of the total operating expenditure for the year and quarter.
  • On July 16, 2025, the Company reported the receipt of $4.58 million for the research and development tax incentive and associated interest for the 2024 financial year.